GlobeNewswire by notified

Roche develops unique PCR tests to detect the monkeypox virus

Share
  • Roche and its subsidiary TIB Molbiol have developed three different LightMix® Modular Virus kits for the detection of the monkeypox virus
  • Multiple clusters of monkeypox virus have been reported in non-endemic countries, and the World Health Organization (WHO) expects more cases will be identified as surveillance expands
  • Use of these new research test kits assess the spread of the virus and can help monitor the potential impact of therapeutics, vaccines and public health interventions

Basel, 25 May 2022 – Roche (SIX: RO, ROG; OTCQX: RHHBY) and its subsidiary TIB Molbiol have developed three unique LightMix® Modular Virus kits in response to recent monkeypox virus concerns. Multiple clusters of the monkeypox virus have been reported within the past two weeks in several European countries and North America, which are regions where the virus is not normally found.

“Roche has very quickly developed a new suite of tests that detect the monkeypox virus and aid in following its epidemiologic spread,” said Thomas Schinecker, CEO Roche Diagnostics. “Diagnostic tools are crucial for responding to and ultimately controlling emerging public health challenges as they advance response measures such as tracing efforts and treatment strategies.”

The first LightMix Modular Virus kit detects orthopoxviruses, including all monkeypox viruses from both the West African and Central African forms of the virus (referred to as clades).The second kit is a specific test detecting monkeypox viruses only (West African and Central African clade). For researchers interested in obtaining both of these results, a third kit is available that simultaneously detects orthopoxviruses plus provides information on whether a monkeypox virus is present or not (West African and Central African clade).

The test kits are available for research use in the majority of countries worldwide.

About the LightMix® Modular Orthopox / MonkeypoxVirus kits
The LightMix® Modular Orthopox /Monkeypox Virus Kits are assays that detect Orthopoxviruses, including the monkeypox virus, using a technology called quantitative PCR (qPCR). To do this, first sample using an established NA extraction method. The assay is then performed on either a LightCycler® 480 II Instrument or cobas z 480 Analyzer. The kit, reagents and instruments are all available to purchase from the majority of Roche Diagnostics affiliates.

About the virus
Monkeypox was first detected in laboratory monkeys in 1958. The virus is, however, assumed to transmit from wild animals such as rodents to people — or from human to human. In an average year, a few thousand cases occur in Western and Central Africa. But cases outside Africa have been limited to just a handful that are associated with travel to Africa or with the importation of infected animals. Treatments and vaccines that were developed for smallpox are available and are thought to be useful to limit spreading of Monkeypox.1

About Roche
Founded in 1896 in Basel, Switzerland, as one of the first industrial manufacturers of branded medicines, Roche has grown into the world’s largest biotechnology company and the global leader in in-vitro diagnostics. The company pursues scientific excellence to discover and develop medicines and diagnostics for improving and saving the lives of people around the world. We are a pioneer in personalised healthcare and want to further transform how healthcare is delivered to have an even greater impact. To provide the best care for each person we partner with many stakeholders and combine our strengths in Diagnostics and Pharma with data insights from the clinical practice.

In recognising our endeavor to pursue a long-term perspective in all we do, Roche has been named one of the most sustainable companies in the pharmaceuticals industry by the Dow Jones Sustainability Indices for the thirteenth consecutive year. This distinction also reflects our efforts to improve access to healthcare together with local partners in every country we work.

Genentech, in the United States, is a wholly owned member of the Roche Group. Roche is the majority shareholder in Chugai Pharmaceutical, Japan.

For more information, please visit www.roche.com.

All trademarks used or mentioned in this release are protected by law.

References
[1] Kozlov, M., Monkeypox goes global: why scientists are on alert. May 2022. Available at: https://www.nature.com/articles/d41586-022-01421-8. Accessed 23 May 2022.

Roche Group Media Relations
Phone: +41 61 688 8888 / e-mail: media.relations@roche.com

Hans Trees, PhD
Phone: +41 61 687 41 47
SileiaUrech
Phone: +41 79 935 81 48

Dr. Barbara von Schnurbein
Phone: +41 61 687 89 67
KarstenKleine
Phone: +41 61 682 28 31

Nina Mählitz
Phone: +41 79 327 54 74
Nathalie Meetz
Phone: +41 61 687 43 05

Attachment

To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.
To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.

About GlobeNewswire by notified

GlobeNewswire by notified
GlobeNewswire by notified
One Liberty Plaza - 165 Broadway
NY 10006 New York

https://notified.com

GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Subscribe to releases from GlobeNewswire by notified

Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from GlobeNewswire by notified

Kalera Public Limited Company announces its share structure following the business combination with Agrico Acquisition Corp.29.6.2022 16:30:19 CEST | Press release

ORLANDO, Fla., June 29, 2022 (GLOBE NEWSWIRE) -- Kalera Public Limited Company ( “Kalera”) and Agrico Acquisition Corp. (“Agrico”) today announced the completion of their previously announced business combination. The combined company will retain the Kalera name and will commence trading ordinary shares (“Kalera Shares”) and warrants (“Kalera Warrants”) on Nasdaq under the new ticker symbols “KAL” and “KALWW”, respectively, on Wednesday, June 29, 2022. The business combination was approved at a special meeting of the shareholders of Kalera S.A. on June 28, 2022. Update on Share Structure Pursuant to the Sponsor Support Agreement entered into on January 30, 2022, upon the consummation of the business combination approximately 1.8 million shares (50%) of Agrico Class B common stock were first converted into Agrico Class A common stock on a one-for-one basis, then into Kalera Shares on a one-for-one basis. The remaining 50% of the Agrico Class B common stock was forfeited to Agrico. In co

Business School Graduates Enter White-Hot Job Market as Employers Signal Growth, Confidence in Their Credentials29.6.2022 16:00:00 CEST | Press release

MBA and business master’s degrees remain hot commodity despite recession fears and COVID challenges RESTON, Va., June 29, 2022 (GLOBE NEWSWIRE) -- The Graduate Management Admission Council (GMAC), a global association of leading graduate business schools, today released its annual hiring report, the GMAC Corporate Recruiters Survey – 2022 Summary Report. The report explores the state of employer demand for graduate business school talent (MBA and business master’s degree recipients) in the context of the COVID-19 pandemic and includes responses from nearly 1,000 corporate recruiters and staffing firms around the world. While rising inflation and the war in Ukraine were just at the onset during the time when the survey was conducted in February and March 2022, hiring projections of graduate management education (GME) graduates remain bullish this year, with 92 percent of corporate recruiters expecting to hire newly minted MBAs. Promisingly, 2 in 3 responding corporate recruiters describ

AGC Biologics Named Manufacturing Company of the year by American Business Awards29.6.2022 15:09:00 CEST | Press release

Global CDMO honored for Growth in Mammalian, Microbial and Cell and Gene Manufacturing capabilities at Seattle, Boulder and Longmont sites SEATTLE, June 29, 2022 (GLOBE NEWSWIRE) -- AGC Biologics, a leading global Biopharmaceutical Contract Development and Manufacturing Organization (CDMO), today announced it was named Company of the Year in the “Large - Manufacturing” category in the 20th Annual American Business Awards®. The American Business Awards are the U.S.A.’s premier business awards program. Nicknamed the Stevies for the Greek word meaning “crowned,” the awards were presented to winners at a gala ceremony at the Marriott Marquis Hotel in New York on Monday, June 13. More than 230 professionals worldwide participated in the judging process to select this year’s American Business Award winners. AGC Biologics has a global pharmaceutical manufacturing network with seven sites across three continents. Over the last two years, the company has expanded its capabilities and reach with

PGS ASA: Approval and publication of prospectus – Listing of shares and Subsequent Offering29.6.2022 15:01:52 CEST | Press release

29 June, 2022 NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO AUSTRALIA, CANADA, JAPAN, HONG KONG, SOUTH AFRICA OR THE UNITED STATES, OR ANY OTHER JURISDICTION IN WHICH THE RELEASE, PUBLICATION OR DISTRIBUTION WOULD BE UNLAWFUL. THIS ANNOUNCEMENT DOES NOT CONSTITUTE AN OFFER OF ANY OF THE SECURITIES DESCRIBED HEREIN. Reference is made to the previous stock exchange announcements by PGS ASA (“PGS” or the “Company”) regarding a successfully placed private placement (the "Private Placement") of new shares in the Company, raising gross proceeds of approximately NOK 800 million and a potential subsequent offering (the “Subsequent Offering) of up to 38,155,803 new shares at a subscription price of NOK 3.70, and the Company’s extraordinary general meeting’s approval of the same on 27 May 2022. The Private Placement consisted of one tranche of 74,200,000 new shares ("Tranche 1") and a second tranche of 142,016,216 new shares ("Tranche2"). T

ASM INTERNATIONAL N.V. ANNOUNCES DETAILS OF THE Q2 2022 CONFERENCE CALL AND WEBCAST29.6.2022 15:00:00 CEST | Press release

Almere, The Netherlands June 29, 2022 ASM International N.V. (Euronext Amsterdam: ASM) will report its second quarter 2022 financial results at approximately 6:00 p.m. CET on Wednesday, July 20, 2022. ASM will host the quarterly earnings conference call and webcast on Thursday, July 21, 2022, at 3:00 p.m. CET. Conference call participants should pre-register using this link to receive the dial-in numbers and a personal PIN, which are required to access the conference call. A simultaneous audio webcast, and replay will be accessible at www.asm.com/investors/webcasts-presentations/2022/second-quarter-earnings. About ASM International ASM International N.V., headquartered in Almere, the Netherlands, and its subsidiaries design and manufacture equipment and process solutions to produce semiconductor devices for wafer processing, and have facilities in the United States, Europe, and Asia. ASM International's common stock trades on the Euronext Amsterdam Stock Exchange (symbol: ASM). For mor